PT-141 (Bremelanotide) Sexual Function Impact

What Is PT-141 and How Does It Work?

Bremelanotide is a cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (alpha-MSH). Unlike PDE5 inhibitors such as sildenafil, which act on penile or clitoral vasculature, bremelanotide crosses the blood-brain barrier and binds melanocortin receptors, primarily MC3R and MC4R, in hypothalamic and limbic regions that govern sexual motivation [1]. The result is a centrally mediated increase in dopaminergic and oxytocinergic tone, which translates clinically to greater sexual desire rather than a purely mechanical erection or lubrication response.

Pharmacokinetic Profile

After a 1.75 mg subcutaneous dose, bremelanotide reaches maximum plasma concentration (Cmax) of roughly 9 ng/mL within 1 hour [2]. Its terminal half-life is approximately 2.7 hours. The drug is cleared via peptide hydrolysis rather than CYP450 enzymes, which limits drug-drug interactions but also means that renal insufficiency can extend exposure. The prescribing information from the FDA notes that patients with severe renal impairment (creatinine clearance <30 mL/min) should not use bremelanotide [3].

Central vs. Peripheral Mechanisms

This distinction matters clinically. A patient with HSDD who has adequate genital blood flow but suppressed desire may respond well to bremelanotide where a PDE5 inhibitor would offer little benefit. Conversely, a patient with primary vascular erectile dysfunction is unlikely to derive adequate benefit from bremelanotide alone. The FDA product label frames the indication tightly: "acquired, generalized hypoactive sexual desire disorder (HSDD)," meaning the low desire is not attributable to another medical or psychiatric condition, relationship problems, or medication effects [3].

The RECONNECT Phase 3 Trials: Core Evidence

The primary evidence base for bremelanotide comes from two identically designed, randomized, double-blind, placebo-controlled trials published in Obstetrics and Gynecology in 2019, collectively called RECONNECT [4].

Trial Design

Both studies enrolled premenopausal women aged 21-55 with a DSM-5 diagnosis of HSDD. Participants were randomized 1:1 to bremelanotide 1.75 mg subcutaneous injection or matching placebo, self-administered on an as-needed basis before anticipated sexual activity over 24 weeks. The two co-primary endpoints were change from baseline in the Female Sexual Function Index desire domain score (FSFI-desire) and change from baseline in the Female Sexual Distress Scale-Desire/Arousal/Orgasm item 13 (FSDS-DAO) score, which measures distress about low desire [4].

Key Results

In Study 1 (n=627), bremelanotide produced a mean change of +0.35 points on the FSFI-desire subscale vs. +0.13 for placebo (P<0.001) and a mean decrease of -0.39 on the FSDS-DAO item 13 vs. -0.21 for placebo (P<0.001) [4]. Study 2 (n=620) replicated these findings with comparable effect sizes. Across both studies, approximately 25% of bremelanotide users were classified as responders (defined as at least a 1.2-point improvement in FSFI-desire plus at least a 1.0-point drop in FSDS-DAO) compared with 17% on placebo [4].

The number-needed-to-treat for one additional responder was approximately 13, which is consistent with other centrally acting sexual dysfunction therapies [4].

Satisfying Sexual Events

A secondary endpoint analysis examined the mean number of satisfying sexual events (SSEs) per month. Women on bremelanotide reported 0.7 additional SSEs per month compared with baseline versus 0.4 additional SSEs for placebo. The absolute difference is modest, but the trial population had a mean baseline frequency of roughly 2 SSEs per month, making a 0.3-SSE increment a clinically perceptible change for many participants [4].

What the Guideline Bodies Say

The International Society for the Study of Women's Sexual Health (ISSWSH) published a process-of-care algorithm for HSDD that positions bremelanotide as a first-line pharmacological option alongside flibanserin for premenopausal women who have not responded to psychoeducation or sex therapy [5]. The guideline notes: "Bremelanotide and flibanserin have distinct mechanisms and may be sequentially or, under specialist supervision, concurrently trialed in patients with inadequate response to one agent" [5].

The Endocrine Society's 2019 clinical practice guidelines on female sexual dysfunction acknowledge bremelanotide's approval but recommend that clinicians assess cardiovascular risk before prescribing, given the transient increases in blood pressure observed in pharmacodynamic studies [6].

Side Effects and Safety Profile

Bremelanotide has a predictable and mostly self-limiting side-effect profile rooted in its melanocortin pharmacology.

Nausea: The Dominant Adverse Event

Nausea was the most common adverse event in RECONNECT, occurring in 40.0% of bremelanotide users vs. 1.3% of placebo users [4]. Most episodes were rated mild-to-moderate and resolved within 2 hours without treatment. The FDA label recommends that patients use an antiemetic (the trials used ondansetron 8 mg orally 1 hour before injection in a subset of participants) if nausea is problematic [3]. Nausea rates declined over repeated use in the open-label extension, suggesting some pharmacological tolerance to this side effect [4].

Cardiovascular Signal

Bremelanotide produces a transient, dose-related increase in systolic blood pressure averaging 6 mmHg, with peak effect at 12 hours post-dose [3]. Blood pressure returns to baseline within 12 hours in most patients. For women with well-controlled hypertension (baseline <165/95 mmHg), the label allows use with monitoring, but the drug is contraindicated in patients with cardiovascular disease or uncontrolled hypertension [3].

Hyperpigmentation

Approximately 1% of women in the phase 3 program developed focal hyperpigmentation of the face, gums, or breasts after repeated dosing. The mechanism is MC1R stimulation in melanocytes. The effect may not fully resolve after discontinuation in all patients, which the prescribing information specifically notes as a risk [3].

Drug Interactions

Bremelanotide significantly increases exposure of naloxone and can decrease the rate (not extent) of absorption of orally co-administered drugs due to transient gastroparesis. Patients on oral contraceptives should take them at least 1 hour before bremelanotide injection to avoid absorption delays [3]. Concurrent use with opioid medications or naltrexone is not recommended because naltrexone has MC4R-antagonist properties that may blunt the desired effect.

Dosing and Administration

Standard Protocol

The approved dose is 1.75 mg (the full contents of one autoinjector) injected subcutaneously into the abdomen or thigh 45 minutes before anticipated sexual activity [3]. Patients should not use more than one dose in 24 hours and should not use bremelanotide more than once per calendar day regardless of how many sexual events occur.

Titration and Starting Guidance

There is no approved dose titration. However, clinical practice at centers specializing in sexual medicine has evolved toward having patients self-test an initial dose on a non-sexual-activity day to assess individual nausea susceptibility before using the drug in a partnered context. This off-label clinical practice is not in the FDA label but reflects practical patient-experience considerations.

Storage and Handling

The autoinjector should be stored at room temperature (68-77 degrees Fahrenheit). Unlike peptides such as semaglutide or tesamorelin, bremelanotide does not require refrigeration, which simplifies travel and daily storage for patients [3].

PT-141 in Men: Off-Label Evidence

No FDA indication exists for bremelanotide in men. The off-label evidence base consists of earlier phase 2 work conducted before the drug's formulation shifted from intranasal to subcutaneous delivery.

Intranasal Data

A 2004 randomized crossover study (n=20) published in the International Journal of Impotence Research tested intranasal PT-141 at 7.5 mg and 20 mg in men with erectile dysfunction who had previously responded to sildenafil. Penile circumference increased significantly above placebo for both doses, and subjective reports of sexual desire were enhanced [7]. The intranasal formulation was later abandoned due to hypotension concerns at higher doses, but the mechanistic proof-of-concept in men remained.

Subcutaneous Off-Label Use

The subcutaneous formulation at 1.75 mg is now used off-label in some men's health telehealth settings, often combined with PDE5 inhibitors. No phase 3 RCT in men using the approved formulation and dose has been published as of mid-2025. The American Urological Association's 2024 erectile dysfunction guidelines do not list bremelanotide as a recommended therapy for men, noting insufficient evidence at the approved dose [8].

Clinicians prescribing bremelanotide off-label to men should document the absence of controlled evidence at this dose, obtain informed consent, and monitor blood pressure given the cardiovascular signal seen in the female trials.

Comparing Bremelanotide to Flibanserin

Both bremelanotide and flibanserin (Addyi) are FDA-approved for HSDD in premenopausal women, and the choice between them often comes down to practical factors rather than efficacy differences, since no head-to-head trial exists.

Mechanism Differences

Flibanserin is a 5-HT1A agonist and 5-HT2A antagonist taken daily as a 100 mg oral tablet at bedtime [9]. Its daily requirement means consistent circadian-rhythm effects on serotonin and dopamine. Bremelanotide, by contrast, is on-demand, taken only before anticipated activity. Women who prefer not to commit to daily medication tend to favor bremelanotide, while those who find anticipatory dosing anxiety-provoking may prefer flibanserin.

Alcohol Interaction

Flibanserin carries a boxed warning for CNS depression when combined with alcohol, a restriction that significantly limits its real-world usability. Bremelanotide has no alcohol interaction warning, which is a meaningful practical advantage [3, 9].

Adverse Event Profiles

Flibanserin's primary adverse events are dizziness, somnolence, and hypotension (linked to the alcohol interaction). Bremelanotide's primary events are nausea and transient blood pressure elevation. Neither profile is trivially manageable, but they represent distinct risk considerations depending on patient comorbidities.

Patient Selection and Clinical Decision-Making

Who Is the Ideal Candidate?

Bremelanotide fits best for premenopausal women who meet these criteria: a DSM-5 HSDD diagnosis confirmed by a validated tool such as the Decreased Sexual Desire Screener (DSDS), absence of cardiovascular disease, blood pressure below 165/95 mmHg at baseline, no concurrent naltrexone therapy, and a preference for on-demand rather than daily medication [3, 5]. Women who primarily report arousal or orgasm dysfunction without desire deficits are not the target population, as bremelanotide's mechanism is desire-centric.

Screening Before Prescribing

A reasonable pre-prescription workup includes a baseline blood pressure measurement, a brief cardiovascular history, a review of concurrent medications (particularly opioids and naltrexone), and assessment for thyroid dysfunction and androgen deficiency, as both can cause secondary HSDD that responds better to treating the underlying cause than to bremelanotide [6].

Monitoring After Initiation

Blood pressure should be checked at a follow-up visit within 4-8 weeks of initiation. FSFI scores or validated desire questionnaires taken at 8 and 24 weeks allow objective tracking of response. If a patient reports no subjective benefit after 8 encounters with bremelanotide, the likelihood of eventual response is low, and discontinuation or transition to flibanserin is appropriate per the ISSWSH algorithm [5].

Emerging Research and Pipeline Developments

Research interest in melanocortin pharmacology for sexual function has not stopped at bremelanotide.

Central Mechanisms and HSDD Subtyping

A 2022 review in the Journal of Sexual Medicine proposed that HSDD is heterogeneous, with subgroups driven by dopaminergic hypofunction, serotonergic excess, or oxytocin signaling deficits [10]. Bremelanotide may be most effective in the dopaminergic hypofunction subgroup, which could explain the ~25% responder rate versus an 80-90% responder rate one might expect if HSDD were a homogeneous disorder.

Combination Strategies

Pilot data from small open-label series suggest that combining low-dose testosterone (transdermal 300 mcg/day) with on-demand bremelanotide may produce additive effects on desire scores in women with concurrent androgen deficiency. No randomized controlled trial has tested this combination as of July 2025, and it remains off-label.

Male Hypoactive Sexual Desire Disorder

The FDA has not approved any drug for male HSDD. A peptide analog with greater MC4R selectivity and fewer nausea-inducing MC3R effects is in early preclinical stages at several research institutions. This work positions bremelanotide as a pharmacological proof-of-concept rather than a final product in the male desire space.

Practical Prescribing Notes

Bremelanotide is available only through a network of specialty pharmacies due to the Risk Evaluation and Mitigation Strategy (REMS) program that was required during initial approval but has since been removed. As of 2023, bremelanotide is no longer subject to a REMS, meaning any licensed pharmacy can dispense it with a valid prescription [3]. Generic versions are not yet available, and the branded Vyleesi autoinjector carries a list price near $960 per dose, though manufacturer copay assistance programs bring out-of-pocket costs significantly lower for eligible commercially insured patients.

Compounded bremelanotide from 503A pharmacies is available at lower price points but is not FDA-approved and carries variable purity and potency risk. Clinicians and patients should weigh cost considerations against the regulatory assurance of the branded product.

The FDA label specifically states that bremelanotide "is not indicated for use in men" and "has not been studied in postmenopausal women or in women with surgically induced menopause" [3]. Prescribing in these populations requires explicit off-label informed consent and clinical justification.

A baseline blood pressure of 140/85 mmHg or below before the first dose is the threshold used in most academic sexual medicine practices, even though the label allows use up to 165/95 mmHg, because the transient 6 mmHg systolic rise would still keep most patients below a clinically concerning threshold.